Whitehawk Therapeutics, Inc. — Director's Dealing 2021

Sep 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aadi Bioscience, Inc. (AADI)
CIK: 0001422142
Period of Report: 2021-09-08

Reporting Person: Reeve Emma (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-08	Stock option (right to buy)	$27.67	A	16486	Acquired	2031-09-08	Common Stock (16486)	Direct

Footnotes

F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month) such that all shares of common stock subject to the Initial Award shall be fully vested on the three year anniversary of the grant date. The grant date is September 8, 2021.